Table 3.
Summary of published studies of anti-GBM disease incidence
| Author (Reference) | Year | Country | Source of Cases | Population at Risk | Duration of Study Period, yr | Cases, n | Rate, pmp/yr |
|---|---|---|---|---|---|---|---|
| Canney et al (current study) | 2016 | Ireland | Nationwide study using serology and biopsy data | 4,378,955 | 11 | 79 | 1.64 |
| Taylor et al (9) | 2011 | New Zealand | Serology and biopsy data from a single regional laboratory | 1,279,188 | 10 | 23 | 1.79 |
| Nakabayashi et al (12) | 2011 | Japan | Retrospective single-center study of renal pathology | NA | 10 | 7 | NAa |
| Hirayama et al (13) | 2008 | Japan | National survey of nephrology units | NA | 12 | 47 | NAb |
| Rutgers et al (10) | 2005 | Netherlands | Regional renal biopsy registry | 720,000 | 25 | 13 | 0.7 |
| Li et al (11) | 2004 | China | Single-center experience | 1,500,000c | 11 | 10 | 0.6 |
| Heaf et al (14) | 1999 | Denmark | National renal biopsy registry | 5,200,000 | 11.7 | NA | 0.6 |
| Andrassy et al (8) | 1991 | Germany | Single-center study of RPGN | 930,000 | 5.7 | 3 | 0.57 |
| McPhaul et al (15) | 1976 | United States | Prospective single-center study of consecutive renal biopsies | NA | 3.5 | 43 | NAa |
pmp, per million population; NA, not available; RPGN, rapidly progressive GN.
a
Rate expressed as proportion of biopsy-proven GN.
b
Rate expressed as the proportion of total RPGN cases in the survey.
c
Estimated catchment area of the hospital.